# Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

> **NCT01527539** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 25 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT01527539
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11-23
- **Primary completion:** 2004-10-12
- **Final completion:** 2004-10-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527539, "Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01527539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*